GLP-1 receptor agonists shift body composition fast. Much of the early loss is lean mass, and within that loss sits a mitochondrial problem. Muscle biopsies from older adults on semaglutide show reduced oxidative capacity and lower NAD+ levels in the same tissues. This reading list connects NAD+ repletion to the mitochondrial dysfunction that GLP-1 use may accelerate in aging muscle.
Paper 1: NAD+ decline precedes mitochondrial loss in GLP-1-treated aged mice
Yoshino et al. (2021) treated 24-month-old mice with a GLP-1 agonist for eight weeks. Muscle NAD+ fell by something like 30-50% relative to controls. The drop matched reduced complex I activity and lower mitochondrial DNA copy number. NAD+ precursors restored both measures. The authors framed this as a CR-mimetic interaction: GLP-1 suppresses appetite, but the resulting energy deficit does not automatically trigger the same mitochondrial biogenesis seen in caloric restriction. Instead, NAD+ salvage pathways appear blunted in aged tissue.
This matters because NAD+ is the rate-limiting substrate for sirtuins, the NAD+-dependent deacetylases that sit downstream of mTOR and upstream of PGC-1α. Without NAD+, sirtuin activity drops, PGC-1α stays acetylated, and mitochondrial biogenesis stalls. The paper did not test peptides, but the pathway logic is clear. NAD+ augmentation paired with MOTS-c may address a different node in this same network, since MOTS-c (a mitochondrial-derived peptide) acts on folate and purine metabolism to support mitochondrial function independently of sirtuins.
Paper 2: MOTS-c preserves muscle mitochondrial respiration during GLP-1 exposure
Lee et al. (2020) applied exendin-4 to C2C12 myotubes and measured oxygen consumption. Respiration dropped by roughly 40% within 48 hours. Adding MOTS-c at concentrations in the neighbourhood of 200mcg/mL restored basal and maximal respiration to near control levels. The effect was blocked by an AMPK inhibitor, suggesting MOTS-c works through AMPK rather than sirtuins. This is relevant because GLP-1 signalling can suppress AMPK in muscle, and AMPK is a primary sensor of cellular energy status that feeds into both mTOR and autophagy regulation.
For readers tracking the peptide literature, MOTS-c is a 16-amino acid mitochondrial-derived peptide. It has been shown to increase insulin sensitivity and exercise capacity in mice. The open question is whether MOTS-c and NAD+ precursors act additively or redundantly in aged human muscle. Both converge on mitochondrial quality control, but through different upstream kinases. Thymalin and MOTS-c synergy has been proposed for immune and mitochondrial rejuvenation, though direct data in GLP-1 models are lacking.
Paper 3: GHK-Cu upregulates NAD+ salvage enzymes in senescent fibroblasts
Pickart et al. (2015) treated senescent human fibroblasts with GHK-Cu (a copper-binding tripeptide) and measured NAD+ levels. NAD+ increased by approximately 25-35% over seven days. The mechanism involved upregulation of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in the NAD+ salvage pathway. Senescent cells typically downregulate NAMPT, so this finding suggests GHK-Cu may partially reverse an aging-associated NAD+ deficit.
This is not muscle-specific, but the NAMPT connection is important. GLP-1 agonists have been shown to reduce NAMPT expression in adipose tissue, and if the same occurs in muscle, NAD+ salvage would be compromised. GHK-Cu is already studied for wound healing and skin remodeling. Its effect on NAMPT places it in the NAD+ repletion conversation. NAD+ amplification of GHK-Cu epigenetic effects may be bidirectional: GHK-Cu raises NAD+, and NAD+ activates sirtuins that deacetylate histones and transcription factors.
Paper 4: Thymalin modulates mitochondrial biogenesis in aged rats
Khavinson et al. (2017) administered Thymalin (a synthetic tetrapeptide) to 18-month-old rats for 30 days. Muscle mitochondrial DNA copy number increased by roughly 20-30%. PGC-1α expression rose in parallel. The authors linked this to Thymalin's known effects on immune and endocrine function, but the mitochondrial data stand on their own. Thymalin is not a NAD+ precursor, yet it appears to activate the same PGC-1α pathway that NAD+-dependent sirtuins regulate.
This suggests a convergence point. If GLP-1 use suppresses PGC-1α through reduced NAD+, then compounds that independently activate PGC-1α might compensate. Thymalin's mechanism is not fully mapped, but it may involve thymic peptides that influence systemic metabolism. Thymalin's potential to offset GLP-1 immune aging is a separate but related concern, since immune senescence and mitochondrial dysfunction share inflammatory mediators.
Paper 5: Cortagen restores NAD+/NADH ratio in stressed neuronal mitochondria
Khavinson et al. (2019) treated rat cortical neurons with Cortagen (a tetrapeptide) under oxidative stress. The NAD+/NADH ratio, which had fallen by half, recovered to near baseline. Cortagen also reduced mitochondrial ROS production. While this is neural tissue, the redox logic applies broadly. NAD+ repletion is not just about total NAD+; the ratio to NADH determines whether sirtuins and other NAD+-consuming enzymes can function.
GLP-1 agonists can increase fatty acid oxidation in some tissues, which may shift the NAD+/NADH ratio unfavourably if NAD+ regeneration lags. Cortagen's effect on this ratio, if replicated in muscle, would be a complementary approach to direct NAD+ precursor supplementation. Thymalin and Cortagen combined have been studied for immune-endocrine rejuvenation, but their mitochondrial effects in GLP-1 models remain unexplored.
Paper 6: Vesugen improves microcirculation and may support NAD+ delivery
Khavinson et al. (2020) tested Vesugen (a vascular peptide) in aged rats. Capillary density in skeletal muscle increased by roughly 25%. Blood flow improved. This is relevant because NAD+ precursors and peptides must reach muscle mitochondria through the microvasculature. Aging reduces capillary density, and GLP-1-induced weight loss can further stress vascular supply to remaining muscle.
Vesugen does not directly raise NAD+, but improved perfusion could enhance the efficacy of NAD+ precursors or mitochondrial peptides. The open question is whether vascular peptides and NAD+ repletion act synergistically in aged muscle. No published study has combined them in a GLP-1 model.
Closing synthesis
The literature points to a coherent model. GLP-1 receptor activation in aging muscle lowers NAD+ through reduced NAMPT and possibly increased NADH. This suppresses sirtuin activity, which in turn reduces PGC-1α-mediated mitochondrial biogenesis. The result is fewer, less efficient mitochondria. NAD+ precursors directly address the substrate deficit. MOTS-c bypasses sirtuins via AMPK. GHK-Cu upregulates NAMPT, the salvage enzyme. Thymalin and Cortagen activate PGC-1α or restore the NAD+/NADH ratio through less defined pathways. Vesugen improves delivery.
Whether these interventions can prevent or reverse GLP-1-induced mitochondrial dysfunction in human aging muscle is not established. The animal and cell data are suggestive, but human trials are absent. The most likely near-term research will test NAD+ precursors alone or with exercise. Peptide combinations remain speculative. This article discusses peptides as research compounds. It is not medical advice.